280 related articles for article (PubMed ID: 28758875)
1. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
[TBL] [Abstract][Full Text] [Related]
2. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
3. FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
Zhang D; Whitaker B; Derebe MG; Chiu ML
MAbs; 2018 Apr; 10(3):463-475. PubMed ID: 29359992
[TBL] [Abstract][Full Text] [Related]
4. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
5. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
[TBL] [Abstract][Full Text] [Related]
6. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
7. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
Vaccaro C; Zhou J; Ober RJ; Ward ES
Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antibody functions through Fc multiplications.
Wang Q; Chen Y; Pelletier M; Cvitkovic R; Bonnell J; Chang CY; Koksal AC; O'Connor E; Gao X; Yu XQ; Wu H; Stover CK; Dall'Acqua WF; Xiao X
MAbs; 2017 Apr; 9(3):393-403. PubMed ID: 28102754
[TBL] [Abstract][Full Text] [Related]
9. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
11. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
12. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
13. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
[TBL] [Abstract][Full Text] [Related]
14. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
Derer S; Kellner C; Berger S; Valerius T; Peipp M
Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
[TBL] [Abstract][Full Text] [Related]
15. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
16. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
18. A general Fc engineering platform for the next generation of antibody therapeutics.
Chen D; Zhao Y; Li M; Shang H; Li N; Li F; Wang W; Wang Y; Jin R; Liu S; Li X; Gao S; Tian Y; Li R; Li H; Zhang Y; Du M; Cao Y; Zhang Y; Li X; Huang Y; Hu LA; Li F; Zhang H
Theranostics; 2021; 11(4):1901-1917. PubMed ID: 33408788
[No Abstract] [Full Text] [Related]
19. Engineering therapeutic monoclonal antibodies.
Liu XY; Pop LM; Vitetta ES
Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
[TBL] [Abstract][Full Text] [Related]
20. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.
Moore GL; Chen H; Karki S; Lazar GA
MAbs; 2010; 2(2):181-9. PubMed ID: 20150767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
